Table: radiopharmacology
[['name', 'investigation', 'route of administration', 'in - vitro / in - vivo', 'imaging / non - imaging'], ['i123 - iodide', 'thyroid uptake', 'oral or iv', 'in - vivo', 'non - imaging'], ['i123 - iodide', 'thyroid imaging thyroid metastases imaging', 'oral or iv', 'in - vivo', 'imaging'], ['i123 - o - iodohippurate', 'renal imaging', 'iv', 'in - vivo', 'imaging'], ['i123 - mibg (m - iodobenzylguanidine)', 'neuroectodermal tumour imaging', 'iv', 'in - vivo', 'imaging'], ['i123 - fp - cit', "spect imaging of parkinson 's disease", 'iv', 'in - vivo', 'imaging']]
Statement: the Route Of Administration for both I123 - O - Iodohippurate and I123 - Mibg (m - Iodobenzylguanidine) is Iv
Statement: I123 - Iodide for Investigation Thyroid Uptake has a Route Of Administration of Oral Or Iv , the same as the I123 - Iodide for Investigation Thyroid Imaging Thyroid Metastasis Imaging
Statement: I123 - Iodide for Thyroid Uptake Investigation is Non - Imaging compared to I123 - Iodide for Thyroid Imaging Thyroid Metastasis Imaging which is Imaging
Statement: I123 - O - Iodohippurate and I123 - Mibg (m - Iodobenzylguanidine) are both In - Vivo and have a Route Of Administration of Iv
Statement: Investigation included Spect Imaging Of Parkinson 's Disease and Neuroectodermal Tumour Imaging , both of which had a Route Of Administration of Iv